CRBN
Protein cereblon
As of the edition of 20 October 2026, CRBN (protein cereblon, UniProt Q96SW2) has 8 drugs tested at it and 9 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q96SW2
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 112
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Urinary and reproductive; Digestive system; Nervous system; Infections
- Registered trials of its drugs
- 1,683
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 4 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lenalidomide | Marketed | Phase 4 | Ends 2027 |
| Thalidomide | Marketed | Phase 4 | none listed |
| Pomalidomide | Marketed | Phase 4 | Ends 2031 |
| Iberdomide | Marketed | Phase 3 | Ends 2031 |
| Mezigdomide | Active | Phase 3 | none listed |
| Avadomide | Active | Phase 2 | none listed |
| Cemsidomide | Active | Phase 2 | none listed |
| SP-3164 | Active | Phase 1 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 5 |
| Undetermined | 4 |
| Total on the list | 9 |